| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Saikosaponin F targets TRPA1 (transient receptor potential ankyrin 1) as an antagonist. It inhibits calcium flux induced by polygodial or AITC in HEK293 cells expressing human TRPA1 at concentrations ranging from 0.5 to 1.5 μM. The compound has anti-inflammatory, hepatoprotective, immunomodulatory, and anticancer activities. It inhibits pro-inflammatory cytokine production and protects liver cells from toxin-induced damage. Saikosaponin F is a potent inhibitor of influenza virus replication.
|
|---|---|
| ln Vitro |
In vitro, Saikosaponin F inhibits calcium flux induced by polygodial or AITC in HEK293 cells expressing human TRPA1 at concentrations ranging from 0.5 to 1.5 μM. It has anti-tumor effects on cervical cancer cells in tissue culture. The compound is a potent inhibitor of influenza virus replication. It has anti-inflammatory, hepatoprotective, and immunomodulatory activities. Saikosaponin F inhibits pro-inflammatory cytokine production.
|
| ln Vivo |
In vivo, Saikosaponin F has been studied for its anti-inflammatory, hepatoprotective, immunomodulatory, and anticancer activities. It protects liver cells from toxin-induced damage and regulates immune responses. The compound has anti-tumor effects and inhibits influenza virus replication. It is found within a herb known for treating depression. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro receptor binding assays for Saikosaponin F involve measuring TRPA1 antagonism. Calcium flux is measured using fluorescent calcium indicators in HEK293 cells expressing human TRPA1. The compound is added at varying concentrations (0.5-1.5 μM) and inhibition of polygodial or AITC-induced calcium flux is measured. Anti-inflammatory activity is assessed by measuring pro-inflammatory cytokine production. Antiviral activity is assessed by measuring influenza virus replication inhibition. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for Saikosaponin F are conducted in HEK293 cells expressing TRPA1, cervical cancer cells, and virus-infected cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Calcium flux is measured using fluorescent calcium indicators. Cell viability is assessed by MTT or CCK-8 assays. Antiviral activity is assessed by measuring viral replication. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Saikosaponin F in vivo studies are conducted in animal models of inflammation, liver injury, cancer, and viral infection. Animals are treated with Saikosaponin F via oral administration or injection. Inflammatory markers and liver enzymes are measured. For anti-tumor studies, tumor growth is monitored. For antiviral studies, viral load is measured. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints.
|
| ADME/Pharmacokinetics |
Saikosaponin F (MW 929.15 g/mol, C48H80O17) is a triterpenoid saponin. It is found in Bupleurum chinensis. The compound is soluble in DMSO and other organic solvents. It is stable under recommended storage conditions. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. Saikosaponin F is used in anti-inflammatory, hepatoprotective, and anticancer research.
|
| Toxicity/Toxicokinetics |
Saikosaponin F is generally well-tolerated in preclinical studies. The compound is a natural triterpenoid saponin with established safety profiles. Its anti-inflammatory, hepatoprotective, immunomodulatory, and anticancer activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Reports indicate that Bupleurum contains saikosaponin F, and relevant data is available for reference.
Saikosaponin F is a triterpenoid saponin from Bupleurum chinensis and a TRPA1 antagonist that inhibits calcium flux induced by polygodial or AITC. It has anti-inflammatory, hepatoprotective, immunomodulatory, and anticancer activities. The compound inhibits influenza virus replication and has anti-tumor effects on cervical cancer cells. Its molecular formula is C48H80O17 with a molecular weight of 929.15 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C48H80O17
|
|---|---|
| Molecular Weight |
929.1386
|
| Exact Mass |
928.54
|
| CAS # |
62687-63-2
|
| PubChem CID |
21598300
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.612
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
65
|
| Complexity |
1730
|
| Defined Atom Stereocenter Count |
24
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@H]3CC[C@]4([C@H](C3(C)C)CC[C@@]5([C@@H]4CC=C6[C@]5(C[C@@H]([C@@]7([C@H]6CC(CC7)(C)C)CO)O)C)C)C)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O
|
| InChi Key |
SXILFEBNQCRWAL-VERCZQKXSA-N
|
| InChi Code |
InChI=1S/C48H80O17/c1-22-31(52)33(54)37(58)41(61-22)65-39-26(20-60-40-36(57)34(55)32(53)25(19-49)62-40)63-42(38(59)35(39)56)64-30-12-13-45(6)27(44(30,4)5)11-14-46(7)28(45)10-9-23-24-17-43(2,3)15-16-48(24,21-50)29(51)18-47(23,46)8/h9,22,24-42,49-59H,10-21H2,1-8H3/t22-,24-,25+,26+,27-,28+,29-,30-,31-,32+,33+,34-,35+,36+,37+,38+,39+,40+,41-,42-,45-,46+,47+,48+/m0/s1
|
| Chemical Name |
(2S,3R,4R,5R,6S)-2-[(2R,3S,4R,5R,6R)-6-[[(3S,4aR,6aR,6bS,8S,8aS,12aS,14aR,14bR)-8-hydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4,5-dihydroxy-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~107.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0763 mL | 5.3813 mL | 10.7626 mL | |
| 5 mM | 0.2153 mL | 1.0763 mL | 2.1525 mL | |
| 10 mM | 0.1076 mL | 0.5381 mL | 1.0763 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
